Inhibrx expands credit facility to $500M with Oxford Finance, receives $100M upfront

Inhibrx Biosciences, Inc.

Total facility expanded to $500M; $100M funded immediately as Term C Loan, up to $225M more at lenders' discretion.
Prior to amendment, $175M had been drawn under the original facility.
Issued warrants to purchase 21,457 shares at $93.21 per share in connection with Term C Loan.
Proceeds to support clinical development of ozekibart (INBRX-109) and INBRX-106.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.